Robert Kennedy Jr., now serving as health secretary, is launching initiatives to reduce antidepressant use among Americans, building on concerns he has repeatedly raised about psychiatric medication overuse.
Kennedy's push centers on new policies designed to encourage people currently taking antidepressants to discontinue or reduce their medications. His approach reflects a longstanding skepticism about psychiatric pharmaceuticals that he has voiced publicly for years. The effort signals a potential shift in how federal health agencies approach mental health treatment.
The initiatives come as antidepressant prescribing remains widespread in the United States. According to recent data, roughly one in ten Americans take antidepressants, with usage rates particularly high among adults and older adults. Some mental health advocates and researchers have raised legitimate questions about whether certain prescriptions continue indefinitely without regular reassessment, while others argue that antidepressants remain underutilized for people who genuinely need them.
Mental health experts express caution about broad deprescribing efforts. The American Psychiatric Association and other professional organizations emphasize that antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), provide significant benefits for people with moderate to severe depression. Abrupt discontinuation can trigger withdrawal symptoms and depression relapse.
Researchers studying antidepressant tapering have found that gradual, medically supervised withdrawal under a doctor's care can work for some patients. Studies by investigators at academic medical centers show that carefully managed deprescribing remains safe only when individuals receive ongoing clinical oversight and when symptoms are actually in remission.
The health secretary's policies will likely face resistance from psychiatrists and neurologists who argue that his framing misrepresents how antidepressants function in clinical practice. They note that Kennedy's past statements about psychiatric medications have sometimes oversimplified complex treatment decisions that require individualized assessment.
THE BOTTOM LINE